Sandberg A A, Morgan R, Berger C, Hecht B K, Hecht F
Am J Med. 1984 Jun;76(6):971-82. doi: 10.1016/0002-9343(84)90843-x.
For two decades, cytogenetic studies have been used to rule in (or out) the Philadelphia (Ph1) chromosome associated with chronic myeloid leukemia. Beyond this single purpose, chromosome studies have generally not been utilized in or applied to the practice of hematology-oncology. This report presents male and female patients, teens to 70s in age, with representative hematologic disorders, in whom the cytogenetic findings were useful clinically. These cases illustrate the following principles: (1) hematologic disorders can be characterized by chromosome analysis; (2) chromosome findings help in the diagnosis, prognosis, and treatment of blood diseases; (3) blood and bone marrow samples can be processed routinely for cytogenetic analysis; (4) these samples can be transported long distances from clinic to laboratory; and (5) the contemporary practice of hematology and oncology requires chromosome analysis for fuller evaluation and understanding of hematologic conditions.
二十年来,细胞遗传学研究一直被用于确定(或排除)与慢性粒细胞白血病相关的费城(Ph1)染色体。除了这一单一用途外,染色体研究一般未被用于血液肿瘤学实践或应用于该领域。本报告介绍了年龄从青少年到70多岁的男性和女性患者,他们患有典型的血液系统疾病,其细胞遗传学结果在临床上很有用。这些病例说明了以下原则:(1)血液系统疾病可以通过染色体分析来表征;(2)染色体结果有助于血液疾病的诊断、预后和治疗;(3)血液和骨髓样本可以常规处理用于细胞遗传学分析;(4)这些样本可以从诊所长途运输到实验室;(5)当代血液学和肿瘤学实践需要进行染色体分析,以便更全面地评估和了解血液学状况。